Stay updated on Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial
Sign up to get notified when there's something new on the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page.

Latest updates to the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check50 days agoChange DetectedThe web page has updated its revision number from v2.14.4 to v2.15.0 and changed the date from 2025-01-20 to 2025-04-17.SummaryDifference2%
- Check64 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 20, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference1.0%
- Check100 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check121 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page.